99mTc-MAA vs. 68Ga-MAA as perfusion agents

Alejandro Amor-Coarasa, Andrew Milera, Denny A. Carvajal, Anthony J. McGoron

Research output: Chapter in Book/Report/Conference proceedingConference contribution

2 Citations (Scopus)

Abstract

The use of 99mTc Macroaggregated Albumin (MAA) as a perfusion agent has been evaluated since 1965. With the advent of Positron Emission Tomography (PET), an initial attempt to produce pharmaceutical grade 68Ga-MAA was successfully performed in 1989. However, a comparison of both perfusion agents, beyond the advantages of PET over Single Photon Emission Tomography (SPET) has not been performed to date. Both 99mTc-MAA and 68Ga-MAA were used to perform lung perfusion studies in male Sprague Dawley rats. Images were taken at several time points. Animals were euthanized at 2 and 4 hours, organs collected and biodistribution determined. Biodistribution of both agents was very similar within the first hour; however, 99mTc is released from the MAA after the first hour and it is excreted into the urine. 68Ga-MAA remains stable until 68Ga decays and more than 95% of the injected activity is concentrated in lungs. The previously reported 6 hour "in vivo" half-life of MAA is challenged. Both imaging agents are suitable for lung perfusion studies. However, the observed half-life of MAA, greater than 6 hours, has significant implication for other applications. 68Ga- MAA is introduced as a possible candidate for Selective Internal Radiation Treatment Planning agent.

Original languageEnglish (US)
Title of host publicationProceedings - 29th Southern Biomedical Engineering Conference, SBEC 2013
Pages131-132
Number of pages2
DOIs
StatePublished - Aug 5 2013
Externally publishedYes
Event29th Southern Biomedical Engineering Conference, SBEC 2013 - Miami, FL, United States
Duration: May 3 2013May 5 2013

Publication series

NameProceedings - 29th Southern Biomedical Engineering Conference, SBEC 2013

Conference

Conference29th Southern Biomedical Engineering Conference, SBEC 2013
CountryUnited States
CityMiami, FL
Period5/3/135/5/13

Fingerprint

Positron emission tomography
Drug products
Tomography
Rats
Animals
Photons
Imaging techniques
Radiation
Planning

ASJC Scopus subject areas

  • Biomedical Engineering

Cite this

Amor-Coarasa, A., Milera, A., Carvajal, D. A., & McGoron, A. J. (2013). 99mTc-MAA vs. 68Ga-MAA as perfusion agents. In Proceedings - 29th Southern Biomedical Engineering Conference, SBEC 2013 (pp. 131-132). [6525711] (Proceedings - 29th Southern Biomedical Engineering Conference, SBEC 2013). https://doi.org/10.1109/SBEC.2013.74

99mTc-MAA vs. 68Ga-MAA as perfusion agents. / Amor-Coarasa, Alejandro; Milera, Andrew; Carvajal, Denny A.; McGoron, Anthony J.

Proceedings - 29th Southern Biomedical Engineering Conference, SBEC 2013. 2013. p. 131-132 6525711 (Proceedings - 29th Southern Biomedical Engineering Conference, SBEC 2013).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Amor-Coarasa, A, Milera, A, Carvajal, DA & McGoron, AJ 2013, 99mTc-MAA vs. 68Ga-MAA as perfusion agents. in Proceedings - 29th Southern Biomedical Engineering Conference, SBEC 2013., 6525711, Proceedings - 29th Southern Biomedical Engineering Conference, SBEC 2013, pp. 131-132, 29th Southern Biomedical Engineering Conference, SBEC 2013, Miami, FL, United States, 5/3/13. https://doi.org/10.1109/SBEC.2013.74
Amor-Coarasa A, Milera A, Carvajal DA, McGoron AJ. 99mTc-MAA vs. 68Ga-MAA as perfusion agents. In Proceedings - 29th Southern Biomedical Engineering Conference, SBEC 2013. 2013. p. 131-132. 6525711. (Proceedings - 29th Southern Biomedical Engineering Conference, SBEC 2013). https://doi.org/10.1109/SBEC.2013.74
Amor-Coarasa, Alejandro ; Milera, Andrew ; Carvajal, Denny A. ; McGoron, Anthony J. / 99mTc-MAA vs. 68Ga-MAA as perfusion agents. Proceedings - 29th Southern Biomedical Engineering Conference, SBEC 2013. 2013. pp. 131-132 (Proceedings - 29th Southern Biomedical Engineering Conference, SBEC 2013).
@inproceedings{e0f7d567edff40f3bad115c123ceb7f3,
title = "99mTc-MAA vs. 68Ga-MAA as perfusion agents",
abstract = "The use of 99mTc Macroaggregated Albumin (MAA) as a perfusion agent has been evaluated since 1965. With the advent of Positron Emission Tomography (PET), an initial attempt to produce pharmaceutical grade 68Ga-MAA was successfully performed in 1989. However, a comparison of both perfusion agents, beyond the advantages of PET over Single Photon Emission Tomography (SPET) has not been performed to date. Both 99mTc-MAA and 68Ga-MAA were used to perform lung perfusion studies in male Sprague Dawley rats. Images were taken at several time points. Animals were euthanized at 2 and 4 hours, organs collected and biodistribution determined. Biodistribution of both agents was very similar within the first hour; however, 99mTc is released from the MAA after the first hour and it is excreted into the urine. 68Ga-MAA remains stable until 68Ga decays and more than 95{\%} of the injected activity is concentrated in lungs. The previously reported 6 hour {"}in vivo{"} half-life of MAA is challenged. Both imaging agents are suitable for lung perfusion studies. However, the observed half-life of MAA, greater than 6 hours, has significant implication for other applications. 68Ga- MAA is introduced as a possible candidate for Selective Internal Radiation Treatment Planning agent.",
author = "Alejandro Amor-Coarasa and Andrew Milera and Carvajal, {Denny A.} and McGoron, {Anthony J.}",
year = "2013",
month = "8",
day = "5",
doi = "10.1109/SBEC.2013.74",
language = "English (US)",
isbn = "9780769550329",
series = "Proceedings - 29th Southern Biomedical Engineering Conference, SBEC 2013",
pages = "131--132",
booktitle = "Proceedings - 29th Southern Biomedical Engineering Conference, SBEC 2013",

}

TY - GEN

T1 - 99mTc-MAA vs. 68Ga-MAA as perfusion agents

AU - Amor-Coarasa, Alejandro

AU - Milera, Andrew

AU - Carvajal, Denny A.

AU - McGoron, Anthony J.

PY - 2013/8/5

Y1 - 2013/8/5

N2 - The use of 99mTc Macroaggregated Albumin (MAA) as a perfusion agent has been evaluated since 1965. With the advent of Positron Emission Tomography (PET), an initial attempt to produce pharmaceutical grade 68Ga-MAA was successfully performed in 1989. However, a comparison of both perfusion agents, beyond the advantages of PET over Single Photon Emission Tomography (SPET) has not been performed to date. Both 99mTc-MAA and 68Ga-MAA were used to perform lung perfusion studies in male Sprague Dawley rats. Images were taken at several time points. Animals were euthanized at 2 and 4 hours, organs collected and biodistribution determined. Biodistribution of both agents was very similar within the first hour; however, 99mTc is released from the MAA after the first hour and it is excreted into the urine. 68Ga-MAA remains stable until 68Ga decays and more than 95% of the injected activity is concentrated in lungs. The previously reported 6 hour "in vivo" half-life of MAA is challenged. Both imaging agents are suitable for lung perfusion studies. However, the observed half-life of MAA, greater than 6 hours, has significant implication for other applications. 68Ga- MAA is introduced as a possible candidate for Selective Internal Radiation Treatment Planning agent.

AB - The use of 99mTc Macroaggregated Albumin (MAA) as a perfusion agent has been evaluated since 1965. With the advent of Positron Emission Tomography (PET), an initial attempt to produce pharmaceutical grade 68Ga-MAA was successfully performed in 1989. However, a comparison of both perfusion agents, beyond the advantages of PET over Single Photon Emission Tomography (SPET) has not been performed to date. Both 99mTc-MAA and 68Ga-MAA were used to perform lung perfusion studies in male Sprague Dawley rats. Images were taken at several time points. Animals were euthanized at 2 and 4 hours, organs collected and biodistribution determined. Biodistribution of both agents was very similar within the first hour; however, 99mTc is released from the MAA after the first hour and it is excreted into the urine. 68Ga-MAA remains stable until 68Ga decays and more than 95% of the injected activity is concentrated in lungs. The previously reported 6 hour "in vivo" half-life of MAA is challenged. Both imaging agents are suitable for lung perfusion studies. However, the observed half-life of MAA, greater than 6 hours, has significant implication for other applications. 68Ga- MAA is introduced as a possible candidate for Selective Internal Radiation Treatment Planning agent.

UR - http://www.scopus.com/inward/record.url?scp=84880854802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880854802&partnerID=8YFLogxK

U2 - 10.1109/SBEC.2013.74

DO - 10.1109/SBEC.2013.74

M3 - Conference contribution

AN - SCOPUS:84880854802

SN - 9780769550329

T3 - Proceedings - 29th Southern Biomedical Engineering Conference, SBEC 2013

SP - 131

EP - 132

BT - Proceedings - 29th Southern Biomedical Engineering Conference, SBEC 2013

ER -